Botulinum toxin type A
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hemifacial Spasm
Conditions
Hemifacial Spasm
Trial Timeline
Dec 1, 2005 โ Jan 1, 2007
NCT ID
NCT00276315About Botulinum toxin type A
Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Hemifacial Spasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00276315. Target conditions include Hemifacial Spasm.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03017729 | Pre-clinical | Completed |
| NCT02969356 | Approved | Completed |
| NCT02020980 | Pre-clinical | Completed |
| NCT02106351 | Phase 3 | Completed |
| NCT01753336 | Phase 3 | Completed |
| NCT01753349 | Pre-clinical | Completed |
| NCT01682148 | Phase 3 | Terminated |
| NCT01313312 | Phase 3 | Completed |
| NCT01251380 | Phase 3 | Completed |
| NCT01251367 | Phase 3 | Completed |
| NCT00455637 | Phase 2 | Terminated |
| NCT00288509 | Phase 3 | Completed |
| NCT00276315 | Phase 3 | Completed |
| NCT00246142 | Phase 3 | Completed |
| NCT00134810 | Phase 2 | Completed |
| NCT00149240 | Phase 2 | Completed |
| NCT00246155 | Phase 3 | Completed |
| NCT00447772 | Phase 3 | Completed |
| NCT00247559 | Phase 2 | Completed |
| NCT00210444 | Phase 2 | Completed |